Compare Fox Corp Class A (FOXA) vs Hims and Hers Health Inc (HIMS) Price & Performance

FOXA trades at $63.42, up 1.15% with a bullish technical signal and strong fundamental performance. The stock shows robust earnings momentum with three consecutive quarterly beats and solid profitability metrics including 14.29% ROE and 9.84% net margin. Recent news highlights the pending Roku acquisition and regulatory scrutiny, while institutional activity shows CEO Lachlan Murdoch's significant $10.3 million share purchase in September 2026.

The outlook remains positive with a $72 consensus price target representing 13.5% upside potential. Key opportunities include continued earnings growth and strategic acquisitions, while risks center on regulatory approval for the Roku deal and potential market volatility. With no analyst sell ratings and strong institutional support, FOXA presents a compelling investment case in the media sector.

Hims & Hers Health (HIMS) trades at $29.38, down 0.54% on the day, amid a bearish technical signal and mixed earnings history. The company reported revenue of $2.35 billion in 2025 with a net income of $128.37 million, but 2026 projections show a net loss of $142 million. Valuation ratios are elevated with a P/E of 57.14 and EV/EBITDA of 205.86. Recent news highlights multiple securities class action lawsuits filed against the company, creating investor uncertainty.

The outlook is cautious due to profitability concerns and legal risks. Analyst consensus is a Hold with a $32.17 price target, suggesting limited upside. Key risks include ongoing litigation, negative profit margins, and high valuation multiples. Investment appeal hinges on the company's ability to return to profitability and navigate regulatory challenges.